Comparing new immunotherapy to Keytruda for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new medicine (HLX17) against a standard immunotherapy drug (Keytruda) as a first treatment for advanced non-squamous non-small cell lung cancer. The goal is to see if the new medicine works just as well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-squamous non-small cell lung cancer that cannot be removed by surgery or treated with radiation.
- Your cancer does not have changes in EGFR, ALK, or ROS1 genes (your doctor can test for this).
- You have not had any previous treatment for your advanced lung cancer.
- You are physically active enough to take care of yourself and are up and about more than half of your waking hours (ECOG 0 or 1).
- You do not have active brain metastases, active autoimmune disease, or a weak immune system (including from HIV or hepatitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
This trial tests a new combination of drugs (HLX07, serplulimab, and chemotherapy) for people with advanced squamous non-small cell lung cancer that hasn't been treated before. The goal is to see if this combo works better than the current standard treatments.
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new drug called HLX37 combined with chemotherapy for people with advanced non-small cell lung cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and works better than chemotherapy alone.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.